Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30O5 |
Molecular Weight | 362.4607 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CCC(=O)C=C2CC[C@@]3([H])[C@]4([H])CC[C@](C(=O)CO)([C@@]4(C)C[C@@]([H])([C@@]31[H])O)O
InChI
InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
Molecular Formula | C21H30O5 |
Molecular Weight | 362.4607 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00741Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00741
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf
Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). Hydrocortisone is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/580108
Curator's Comment:: shown in dogs
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00741 |
|||
Target ID: CHEMBL2034 |
|||
Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10455320 |
50.0 nM [IC50] | ||
Target ID: P04083 Gene ID: 301.0 Gene Symbol: ANXA1 Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00741 |
|||
Target ID: CHEMBL3070 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669853 |
0.1 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Cortef Approved UseCORTEF Tablets are indicated in the following conditions.
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)
Congenital adrenal hyperplasia
Non suppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Epicondylitis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment:
Seasonal or perennial allergic rhinitis
Serum sickness
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Drug hypersensitivity reactions
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its
adnexa such as:
Allergic conjunctivitis
Keratitis
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Iritis and iridocyclitis
Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
7. Respiratory Diseases
Symptomatic sarcoidosis
Loeffler’s syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement Launch Date-5.38012811E11 |
|||
Primary | Cortef Approved UseCORTEF Tablets are indicated in the following conditions.
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)
Congenital adrenal hyperplasia
Non suppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Epicondylitis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment:
Seasonal or perennial allergic rhinitis
Serum sickness
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Drug hypersensitivity reactions
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its
adnexa such as:
Allergic conjunctivitis
Keratitis
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Iritis and iridocyclitis
Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
7. Respiratory Diseases
Symptomatic sarcoidosis
Loeffler’s syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement Launch Date-5.38012811E11 |
|||
Palliative | Cortef Approved UseCORTEF Tablets are indicated in the following conditions.
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)
Congenital adrenal hyperplasia
Non suppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Epicondylitis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment:
Seasonal or perennial allergic rhinitis
Serum sickness
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Drug hypersensitivity reactions
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its
adnexa such as:
Allergic conjunctivitis
Keratitis
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Iritis and iridocyclitis
Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
7. Respiratory Diseases
Symptomatic sarcoidosis
Loeffler’s syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement Launch Date-5.38012811E11 |
|||
Primary | Cortef Approved UseCORTEF Tablets are indicated in the following conditions.
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)
Congenital adrenal hyperplasia
Non suppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Epicondylitis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment:
Seasonal or perennial allergic rhinitis
Serum sickness
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Drug hypersensitivity reactions
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its
adnexa such as:
Allergic conjunctivitis
Keratitis
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Iritis and iridocyclitis
Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
7. Respiratory Diseases
Symptomatic sarcoidosis
Loeffler’s syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement Launch Date-5.38012811E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
258 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2050835 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1162 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2050835 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.82 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2050835 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCORTISONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.9% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/13700365 |
HYDROCORTISONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 4 times / day multiple, intramuscular Highest studied dose Dose: 200 mg, 4 times / day Route: intramuscular Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, 56 years (tange: 40-64 years) n = 10 Health Status: unhealthy Condition: primary adrenal insufficiency Age Group: 56 years (tange: 40-64 years) Sex: M+F Population Size: 10 Sources: |
|
200 mg 4 times / day multiple, intravenous Highest studied dose Dose: 200 mg, 4 times / day Route: intravenous Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, 56 years (tange: 40-64 years) n = 10 Health Status: unhealthy Condition: primary adrenal insufficiency Age Group: 56 years (tange: 40-64 years) Sex: M+F Population Size: 10 Sources: |
|
200 mg 4 times / day multiple, oral Highest studied dose Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, 56 years (tange: 40-64 years) n = 10 Health Status: unhealthy Condition: primary adrenal insufficiency Age Group: 56 years (tange: 40-64 years) Sex: M+F Population Size: 10 Sources: |
|
200 mg single, intravenous Highest studied dose Dose: 200 mg Route: intravenous Route: single Dose: 200 mg Sources: |
unhealthy, 56 years (tange: 40-64 years) n = 10 Health Status: unhealthy Condition: primary adrenal insufficiency Age Group: 56 years (tange: 40-64 years) Sex: M+F Population Size: 10 Sources: |
|
2.5 % 4 times / day multiple, topical Dose: 2.5 %, 4 times / day Route: topical Route: multiple Dose: 2.5 %, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
|
1 mg/kg 4 times / day multiple, intravenous Dose: 1 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 1 mg/kg, 4 times / day Sources: |
unhealthy, children n = 23 Health Status: unhealthy Condition: vasoactive infusion Age Group: children Population Size: 23 Sources: |
Other AEs: Infection... Other AEs: Infection (below serious, 6 patients) Sources: |
0.5 mg/kg 4 times / day multiple, intravenous Dose: 0.5 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 0.5 mg/kg, 4 times / day Sources: |
unhealthy, neonate n = 6 Health Status: unhealthy Condition: Cardiovascular Insufficiency Age Group: neonate Population Size: 6 Sources: |
Other AEs: Hyperbilirubinemia, Hypertension... Other AEs: Hyperbilirubinemia (serious, 1 patient) Sources: Hypertension (serious, 1 patient) Adrenal insufficiency (serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Infection | below serious, 6 patients | 1 mg/kg 4 times / day multiple, intravenous Dose: 1 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 1 mg/kg, 4 times / day Sources: |
unhealthy, children n = 23 Health Status: unhealthy Condition: vasoactive infusion Age Group: children Population Size: 23 Sources: |
Adrenal insufficiency | serious, 1 patient | 0.5 mg/kg 4 times / day multiple, intravenous Dose: 0.5 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 0.5 mg/kg, 4 times / day Sources: |
unhealthy, neonate n = 6 Health Status: unhealthy Condition: Cardiovascular Insufficiency Age Group: neonate Population Size: 6 Sources: |
Hyperbilirubinemia | serious, 1 patient | 0.5 mg/kg 4 times / day multiple, intravenous Dose: 0.5 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 0.5 mg/kg, 4 times / day Sources: |
unhealthy, neonate n = 6 Health Status: unhealthy Condition: Cardiovascular Insufficiency Age Group: neonate Population Size: 6 Sources: |
Hypertension | serious, 1 patient | 0.5 mg/kg 4 times / day multiple, intravenous Dose: 0.5 mg/kg, 4 times / day Route: intravenous Route: multiple Dose: 0.5 mg/kg, 4 times / day Sources: |
unhealthy, neonate n = 6 Health Status: unhealthy Condition: Cardiovascular Insufficiency Age Group: neonate Population Size: 6 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/30/9/1029.long Page: - |
yes [EC50 0.6 uM] | |||
Page: - |
yes [IC50 33.4 uM] | |||
Page: - |
yes [IC50 33.4 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/26387653/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
major |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. | 1999 Dec 24 |
|
Delayed generalized allergic reactions to corticosteroids. | 2000 |
|
[A senile case of acute necrotizing myopathy presenting prolonged severe muscle paralysis due to high dose glucocorticoid and muscle relaxant]. | 2000 Mar |
|
Effect of ruminations on the saliva cortisol response to a social stressor. | 2001 Apr |
|
Circulatory support of the sick preterm infant. | 2001 Feb |
|
Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms. | 2001 Feb |
|
Plasma adrenocorticotropin and cortisol concentrations during acute hypoxemia after a reversible period of adverse intrauterine conditions in the ovine fetus during late gestation. | 2001 Feb |
|
PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. | 2001 Feb |
|
Postnatal glucocorticoids in very preterm infants: "the good, the bad, and the ugly"? | 2001 Feb |
|
Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. | 2001 Feb |
|
Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth. | 2001 Feb |
|
Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. | 2001 Feb |
|
The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. | 2001 Feb |
|
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. | 2001 Feb |
|
Electrophysiological effects of corticosteroids on the retinal pigment epithelium. | 2001 Feb |
|
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. | 2001 Feb |
|
Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. | 2001 Feb |
|
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. | 2001 Feb |
|
Green fluorescent protein mutant as label in homogeneous assays for biomolecules. | 2001 Feb 1 |
|
Post-dexamethasone cortisol level and memory performance in elderly depressed patients. | 2001 Feb 2 |
|
Effects of cortisol on chloride cells in the gill epithelium of Japanese eel, Anguilla japonica. | 2001 Jan |
|
Adrenocortical dysfunction following etomidate induction in emergency department patients. | 2001 Jan |
|
Short-term 17beta-estradiol decreases glucose R(a) but not whole body metabolism during endurance exercise. | 2001 Jan |
|
Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. | 2001 Jan |
|
Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia. | 2001 Jan |
|
Crystallization of hydrocortisone acetate: influence of polymers. | 2001 Jan 16 |
|
The use of chitosan gels as matrices for electrically-modulated drug delivery. | 2001 Jan 29 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: Many Hydrocortisone products are used topically https://www.drugs.com/pro/hydrocortisone.html
The initial dosage of CORTEF (Hydrocortisone) Tablets may vary from 20 mg to 240 mg of hydrocortisone per day depending on the specific disease entity being treated.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11968738
Hydrocortisone concentration-dependently inhibited the current induced by 3 x 10(-5) M ACh with a half maximum inhibitory concentration (IC50) of 2.1 x 10(-4) M (in rats).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:49:03 UTC 2021
by
admin
on
Fri Jun 25 20:49:03 UTC 2021
|
Record UNII |
WI4X0X7BPJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
485
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S01CB03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QA01AC03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
53346-3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S02CA03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS01CA03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS03CA04
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1662A
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QR01AD60
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S01CA03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
FDA ORPHAN DRUG |
234906
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
2144-4
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
PLENADREN (AUTHORIZED: ADRENAL INSUFFICIENCY)
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S03CA04
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
44310-1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
35202-1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
78988-3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
14675-3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QD07AA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS02BA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
32310-5
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/06/372
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS02CA03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
D07AA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QA07EA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1484D
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QH02AB09
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
26828-4
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
51844-9
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QC05AA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
A01AC03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
FDA ORPHAN DRUG |
487515
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS01BB01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1132
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
15043-3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
R01AD60
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QD07XA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
53337-2
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QD07BA04
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1484I
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
EPA PESTICIDE CODE |
6312
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS01BA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S01BB01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
83089-3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1484H
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
FDA ORPHAN DRUG |
467014
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
53336-4
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
83090-1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
D07BA04
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
28550-2
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
D07CA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
83088-5
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
50848-1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
H02AB09
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
33257-7
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
2142-8
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
11155-9
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S02BA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QD07CA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
A07EA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
76352-4
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
C05AA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
17.3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
20622-7
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.3
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
50336-7
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
53345-5
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
S01BA02
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-ATC |
D07XA01
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
WHO-VATC |
QS01CB03
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
FDA ORPHAN DRUG |
716719
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
83091-9
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.1204
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
14158-0
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
45184-9
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
NCI_THESAURUS |
C2323
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
76347-4
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
FDA ORPHAN DRUG |
441614
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
||
|
LOINC |
2143-6
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5492
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | RxNorm | ||
|
1316004
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | USP-RS | ||
|
38
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
Hydrocortisone
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
Hydrocortisone, Topical
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
DB00741
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
5754
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
WI4X0X7BPJ
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
CORTISOL
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
2868
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
50-23-7
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
SUB08065MIG
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
M6094
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | Merck Index | ||
|
1388
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
CHEMBL389621
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
C555
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
HYDROCORTISONE
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water and ether R; sparingly soluble in ethanol (~750 g/l) TS and acetone R. Category: Adrenocortical steroid. Storage: Hydrocortisone should be kept in a well-closed container, protected from light. Additional information: Hydrocortisone melts at about 214?C with decomposition. Definition: Hydrocortisone contains not less than 97.0% and not more than 102.0% of C21H30O5, calculated with reference to the dried substance. | ||
|
3339
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
50-23-7
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
200-020-1
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY | |||
|
D006854
Created by
admin on Fri Jun 25 20:49:03 UTC 2021 , Edited by admin on Fri Jun 25 20:49:03 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
2.4 FOLD INDUCTION OF GR MMTV-liciferase reporter gene
AGONIST
FOLD INDUCTION
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TARGET -> AGONIST |
2.4 FOLD INDUCTION OF GR MMTV-luciferase reporter gene
AGONIST
FOLD INDUCTION
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
PARENT -> METABOLITE ACTIVE |
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity E by 2.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity D by 1.8
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |